AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Global Industrial Company to Report Q3 2025 Earnings on October 28, 2025.
ByAinvest
Monday, Oct 20, 2025 8:21 am ET1min read
Cardiol Therapeutics Inc. (CRDL) trading resumes on the TSX at 8:00 AM ET after a temporary suspension imposed by the Canadian Investment Regulatory Organization (CIRO) to ensure a fair and orderly market. CIRO oversees trading activity on debt and equity marketplaces in Canada.
Cardiol Therapeutics Inc. (CRDL) trading resumed on the Toronto Stock Exchange (TSX) at 8:00 AM ET on September 12, 2025, following a temporary suspension imposed by the Canadian Investment Regulatory Organization (CIRO). The suspension was implemented to ensure a fair and orderly market, as CIRO oversees trading activities on debt and equity marketplaces in Canada.The suspension was likely in response to recent developments in the company's financial and operational status. Cardiol Therapeutics, a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease, has been actively involved in securing funding and advancing its pipeline of drug candidates.
In October 2025, Cardiol Therapeutics successfully completed a private placement offering, raising US$11 million. This funding will support the company's operations into the third quarter of 2027 and strengthen its balance sheet, according to a . The company has been actively pursuing clinical development of its drug candidates, including CardiolRx™, which is in the pivotal Phase III MAVERIC trial for recurrent pericarditis, and CRD-38, a next-generation therapy for heart failure.
The MAVERIC trial, which is fully funded through to a planned New Drug Application submission with the FDA, has seen significant momentum in patient recruitment. The company expects to present data from the ARCHER trial at a cardiology conference in November 2025, which highlights the magnitude of reduction in left ventricular (LV) mass and its potential impact on heart failure, as noted in that press release.
The suspension of trading may have been a precautionary measure to address any potential market volatility or to ensure that investors have access to accurate and up-to-date information. As trading resumes, investors will be closely watching Cardiol Therapeutics' progress in its clinical trials and the broader market response to its recent financial activities.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet